Overview

Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia

Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase Ib clinical study of TPN672 maleate in patients with schizophrenia
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu Kanion Pharmaceutical Co., Ltd
Collaborator:
Shanghai Mental Health Center
Treatments:
Maleic acid